Skip to main content

ZYME

Stock
Health Care
Biotechnology

Performance overview

ZYME Price
Price Chart

Forward-looking statistics

Beta
0.94
Risk
49.96%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Company info

SectorHealth Care
IndustryBiotechnology
Employees306
Market cap$641.3M

Fundamentals

Enterprise value$627.7M
Revenue$93.4M
Revenue per employee—
Profit margin-121.73%
Debt to equity5.68

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.50
Dividend per share—
Revenue per share$1.24
Avg trading volume (30 day)$6M
Avg trading volume (10 day)$8M
Put-call ratio—

Macro factor sensitivity

Growth+4.2
Credit+3.1
Liquidity-2.5
Inflation+0.7
Commodities+0.2
Interest Rates-2.1

Valuation

Dividend yield0.00%
PEG Ratio-7.76
Price to sales10.45
P/E Ratio-7.76
Enterprise Value to Revenue6.72
Price to book2.79

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

Zymeworks (ZYME) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (June 20, 2025)
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

On Wednesday, Zymeworks Inc. ZYME released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents.

Benzinga (March 6, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free